Arcus Biosciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RCUS research report →
Companywww.arcusbio.com
Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy.
- CEO
- Terry J. Rosen
- IPO
- 2018
- Employees
- 627
- HQ
- Hayward, CA, US
Price Chart
Valuation
- Market Cap
- $2.39B
- P/E
- -8.07
- P/S
- 10.13
- P/B
- 5.68
- EV/EBITDA
- -6.75
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 97.03%
- Op Margin
- -168.64%
- Net Margin
- -156.36%
- ROE
- -68.97%
- ROIC
- -50.51%
Growth & Income
- Revenue
- $247.00M · -4.26%
- Net Income
- $-353,000,000 · -24.73%
- EPS
- $-3.29 · -4.78%
- Op Income
- $-386,000,000
- FCF YoY
- -175.00%
Performance & Tape
- 52W High
- $28.72
- 52W Low
- $7.91
- 50D MA
- $23.47
- 200D MA
- $19.49
- Beta
- 0.87
- Avg Volume
- 1.23M
Get TickerSpark's AI analysis on RCUS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 16, 25 | Ribas Antoni | other | 5,050 |
| May 11, 26 | Goeltz II Robert C. | sell | 7,763 |
| Jan 23, 26 | Markus Richard | other | 96,000 |
| Jan 23, 26 | Markus Richard | other | 24,000 |
| Jan 23, 26 | ROSEN TERRY J | other | 79,000 |
| Jan 23, 26 | ROSEN TERRY J | other | 315,000 |
| Jan 23, 26 | Jaen Juan C. | other | 31,000 |
| Jan 23, 26 | Jaen Juan C. | other | 126,000 |
| Jan 23, 26 | Tang Carolyn C. | other | 24,000 |
| Jan 23, 26 | Tang Carolyn C. | other | 96,000 |
Our RCUS Coverage
We haven't published any research on RCUS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RCUS Report →